Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Antibody–drug conjugates in solid tumors: a look into novel targets
C Criscitiello, S Morganti, G Curigliano - Journal of hematology & oncology, 2021 - Springer
Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed
to merge the selectivity of monoclonal antibodies with cell killing properties of …
to merge the selectivity of monoclonal antibodies with cell killing properties of …
HER2-targeted therapies beyond breast cancer—An update
J Yoon, DY Oh - Nature Reviews Clinical Oncology, 2024 - nature.com
The receptor tyrosine-kinase HER2 (also known as ErbB2) is a well-established therapeutic
target in patients with breast or gastric cancer selected on the basis of HER2 overexpression …
target in patients with breast or gastric cancer selected on the basis of HER2 overexpression …
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Amplification of and oncogenic mutations in ERBB2, the gene encoding the HER2 receptor
tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate …
tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate …
[HTML][HTML] Therapeutic vaccines for breast cancer: Has the time finally come?
The ability to exploit the immune system as a weapon against cancer has revolutionised the
treatment of cancer patients, especially through immune checkpoint inhibitors (ICIs) …
treatment of cancer patients, especially through immune checkpoint inhibitors (ICIs) …
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Background Trastuzumab deruxtecan is a HER2-directed antibody–drug conjugate
approved by the US Food and Drug Administration and the European Medicines Agency for …
approved by the US Food and Drug Administration and the European Medicines Agency for …
Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs
Simple Summary A proportion of breast tumors bear the oncogenic transmembrane tyrosine
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …
Molecular intrinsic versus clinical subty** in breast cancer: A comprehensive review
Breast cancer is a heterogeneous disease manifesting diversity at the molecular,
histological and clinical level. The development of breast cancer classification was centered …
histological and clinical level. The development of breast cancer classification was centered …
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
Activating mutations in HER2 (ERBB2) drive the growth of a subset of breast and other
cancers and tend to co-occur with HER3 (ERBB3) missense mutations. The HER2 tyrosine …
cancers and tend to co-occur with HER3 (ERBB3) missense mutations. The HER2 tyrosine …
[HTML][HTML] Antibody–drug conjugates for the treatment of breast cancer
Simple Summary Metastatic breast cancer (BC) is currently an incurable disease. Besides
endocrine therapy and targeted agents, chemotherapy is often used in the treatment of this …
endocrine therapy and targeted agents, chemotherapy is often used in the treatment of this …
Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2‐Positive Breast Cancer
In one of every four or five cases of breast cancer, the human epidermal growth factor
receptor‐2 (HER2) gene is overexpressed. These carcinomas are known as HER2‐positive …
receptor‐2 (HER2) gene is overexpressed. These carcinomas are known as HER2‐positive …